Pharmacyclics CEO takes aim at FDA decision-making

Dendreon isn't the only developer that has a beef with the FDA. Pharmalot writes up the case of Pharmacyclics CEO Richard Miller, who has found a soap box on some high profile news outlets to take the agency to task for rejecting the company's cancer drug. Miller's been on CNBC and on the op-ed pages of the Wall Street Journal to make the case that experimental drugs for terminal diseases should be treated differently than traditional meds.

"The FDA seems to be using a one-size-fits-all approach and seems to be regulating drugs that are intended for serious disease, life-threatening diseases, the same way they might regulate a drug that's used to treat a headache," says Miller.

- read the report from Pharmalot

Suggested Articles

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.